Avalo Therapeutics ownership updated by T. Rowe Price

T. Rowe Price Investment Management, Inc. filed an amended ownership report for Avalo Therapeutics Inc. common stock.

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amended ownership report for Avalo Therapeutics Inc. common stock. The firm reports beneficial ownership of 3,670 shares, representing 0.0% of the class, all with sole voting and dispositive power. It states that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.

Key Figures

Shares beneficially owned: 3,670 shares Percent of class owned: 0.0 % Sole voting power: 3,670 shares +1 more

4 metrics

Shares beneficially owned 3,670 shares Avalo Therapeutics Inc. common stock reported by T. Rowe Price Investment Management, Inc.

Percent of class owned 0.0 % Percentage of Avalo Therapeutics Inc. common stock class reported as beneficially owned

Sole voting power 3,670 shares Number of AVTX shares over which T. Rowe Price has sole power to vote

Sole dispositive power 3,670 shares Number of AVTX shares over which T. Rowe Price has sole power to dispose

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Ownership of 5 percent or less of a class

4 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 3670"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 3,670.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 3,670.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 percent or less of a class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in AVTX does T. Rowe Price Investment Management report in this Schedule 13G/A?

T. Rowe Price Investment Management reports beneficial ownership of 3,670 shares of Avalo Therapeutics Inc. common stock, representing 0.0% of the class, with sole voting and dispositive power over all reported shares.

Does T. Rowe Price Investment Management still hold more than 5% of AVTX common stock?

No. T. Rowe Price Investment Management reports ownership of 0.0% of the AVTX common stock class, confirming it holds 5 percent or less of this security class as disclosed in the ownership section.

How many AVTX shares can T. Rowe Price Investment Management vote and dispose of?

T. Rowe Price Investment Management has sole voting power over 3,670 shares and sole dispositive power over 3,670 shares of Avalo Therapeutics Inc. common stock, with no shared voting or dispositive power reported.

What disclaimer does T. Rowe Price Investment Management include about AVTX beneficial ownership?

T. Rowe Price Investment Management states that this filing shall not be construed as an admission that it is the beneficial owner of the securities referenced and that such beneficial ownership is expressly denied in the statement.

Who signed the AVTX ownership report for T. Rowe Price Investment Management?

The ownership report was signed by Ellen York, Vice President of T. Rowe Price Investment Management, Inc., on 08/14/2026, as indicated in the signature block of the Schedule 13G/A amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:41 AM Accepted by SEC EDGAR 08/14/2026 - 10:39 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

AVALO THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

05338F306

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 05338F306

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,670.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,670.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,670.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AVALO THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 05338F306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3670
(b)	Percent of class: 0.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3670
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3670
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026